Inactivation of Stat3 in tumor cells Releasing a brake on immune responses against cancer? by Gamero, Ana M et al.
CANCER CELL : FEBRUARY 2004 111
Alterations in the expression or function
of critical genes that tightly regulate cell
cycle checkpoints, differentiation, cell
survival, and apoptosis and which can
subsequently lead to cell transformation
and oncogenesis has long been a model
for tumor development and progression.
A refinement of this model involves fail-
ure of the host immune response to rec-
ognize tumor cells due to an inherent
property of the tumor cells resulting in
either a switch off, or an active inhibition,
of crosstalk between innate and adaptive
immunity, thus allowing for tumor devel-
opment and progression (Ochsenbein,
2002).
Signal transducers and activators of
transcription (Stat) belong to a family of
latent cytoplasmic factors that are acti-
vated by tyrosine phosphorylation by
members of the Jak tyrosine kinase fam-
ily in response to a variety of cytokines
and growth factors. Stats dimerize and
translocate to the nucleus to induce
expression of critical genes essential in
normal physiological cellular events.
Several investigators have reported
aberrant activation of Stat3 in a variety of
human cancer cell lines, in primary
tumors including lymphoid/myeloid
malignancies and solid tumors as well as
in cell lines transformed with v-Abl and v-
Src (Calo et al., 2003). Nevertheless, this
constitutive activated form of Stat3 is not
due to mutations in Stat3. Constitutive
Stat3 activity occurs due to deregulation
of protein tyrosine kinases or constitutive
release of growth factors that activate
Stat3. Ablation of Stat3 function in trans-
formed or tumor cells can reverse cell
transformation and/or induce apoptosis
in vitro. Interestingly, tumor regression
has been achieved by introduction in vivo
of a dominant-negative Stat3 in tumors
expressing activated Stat3 (Niu et al.,
1999). Furthermore, the role of Stat3 as
a negative regulator of inflammatory
responses became apparent when tar-
geted deletion of Stat3 in specific tissues
was achieved (Stat3 null mice were
embryonic lethal). Deletion of Stat3 in
normal macrophages led to overproduc-
tion of inflammatory cytokines (Takeda et
al., 1999), whereas disruption of Stat3
during hematopoeisis resulted in severe
inflammatory bowel disease and lethality
(Welte et al., 2003).
Recently, Wang et al. (2004) report-
ed in Nature Medicine an elegant model
where Stat3 signaling in tumor cells
plays a pivotal role in the regulation of
tumor immunity (Figure 1). Using differ-
ent tumor lines expressing constitutively
activated Stat3, inhibition of Stat3 by
expression of a dominant-negative form
of Stat3, or by introducing antisense
oligonucleotides leads to tumor expres-
sion of proinflammatory cytokines and
chemokines needed for the activation of
the innate immune response. Stat3 sig-
naling in tumors inhibits the expression
of inflammatory cytokines and evokes
the release of factors that not only
impede dendritic cell maturation and
activation but also the generation of
antigen-specific T cells, giving rise to
immune tolerance. Interruption of Stat3
signaling in tumors reverses this nega-
tive effect, resulting in enhanced ability
of dendritic cells to present antigen, and
consequently leads to T cell activation
and a break in T cell anergy. Activated
dendritic cells had increased surface
expression of MHC class II and CD40
molecules that correlated with produc-
tion of IL-12 and T cell production of IL-2
and IFNg. Given these findings, it 
was noticeable that neutrophils and
macrophages, the other components of
the innate immune system, also showed
restored function when incubated with
supernatants derived from tumor cells
where Stat3 signaling was blocked.
Wang et al. also demonstrated that 
soluble factors released from tumors
expressing activated Stat3 can activate
Stat3 in dendritic cells, therefore pre-
venting their maturation. Both IL-10 and
VEGF signaling through Stat3 have been
reported to inhibit dendritic cell matura-
tion, and these factors are produced in
cells transformed with v-Src, and trans-
formation by v-Src results in increased
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Inactivation of Stat3 in tumor cells: Releasing a brake on immune
responses against cancer?
A model of immune evasion mediated by tumors expressing constitutively activated Stat3 was recently proposed in Nature
Medicine by Wang et al., suggesting opportunities for a new therapeutic approach for cancer.
Figure 1. A model for the role of Stat3 in the regulation of tumor immunity
As shown in the left panel, activated Stat3 in cancer cells serves to constitutively inhibit T cell
activation by inducing factors that impair DC maturation and activation, thus contributing to T
cell tolerance. Conversely, as shown in the right panel, blocking Stat3 in tumor cells allows the
production of factors that enable DC maturation and function, which contributes to T cell-
mediated antitumor responses.
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Stat3 activity. Although VEGF can weak-
ly activate Stat3, the magnitude of Stat3
activation by IL-10 is higher in bone
marrow progenitor cells (BMPCs).
Consistent with these observations,
Wang and coworkers demonstrated that
activation of Stat3 in BMPCs by super-
natants derived from tumor cells or by IL-
10 leads to a reduction in dendritic cell
maturation that was reversed with a
phosphopeptide inhibitor of Stat3. In
contrast, supernatant from Stat3 null
BMPCs do not show any alterations in
dendritic cell maturation, demonstrating
a pivotal role for Stat3 in bridging innate
and adaptive tumor immunity and in the
reversal of systemic tolerance. It remains
to be elucidated whether dendritic cells
from IL-10 null mice are refractory to
Stat3-mediated inhibition of dendritic cell
maturation and whether there are other
tumor-derived factors that need to be
identified that signal through Stat3.
A recent study (Cheng et al., 2003)
also presents strong evidence for pursu-
ing Stat3 as a molecular target to
enhance T cell immunity. These authors
demonstrated that the crucial interaction
of antigen presenting cells (APCs) with T
cells resulting either in T cell activation
versus T cell tolerance relies on the acti-
vation of Stat3 in those APCs. T cell tol-
erance can be reversed if activation of
Stat3 signaling is blocked in APCs. This
resulted in increased expression of MHC
class II molecules and costimulatory
molecules B7-1 and B7-2, expression of
inflammatory cytokines, IL-12, and lack
of IL-10 production by APCs.
Additional studies (Nefedova et al.,
2004) demonstrate the involvement of
Stat3 in abnormal differentiation of den-
dritic cells in cancer. Soluble factors from
tumor cells expressing hyperactivated
Stat3 prevented myeloid cell differentia-
tion into dendritic cells. This was due to
lack of downregulation of Stat3 activity in
hematopoeitic progenitor cells and an
increase in the proportion of immature
myeloid cells. However, this inhibitory
effect was reversible and could be pre-
vented by expression of dominant-nega-
tive Stat3, resulting in a break in T cell
tolerance.
Several mechanisms of tumor eva-
sion by the immune system have been
proposed (Ochsenbein et al., 2001).
Impaired induction of antitumor cytolytic
T cells (CTLs) might be due to deletion of
antigen-specific CTLs by tumor cells or
the inability of tumor cells to reach sec-
ondary lymphoid organs for CTL priming.
Even if some tumor cells penetrate the
lymphoid compartment, an immunologi-
cal tolerant barrier exists, preventing T
cells from recognizing the presence of
tumor cells. One possible explanation for
these observations is the generation of T
cell tolerance mediated by tumor cells
expressing activated Stat3.
Taken all together, these findings
unveil Stat3 as a major player in linking
innate and adaptive tumor immunity.
STAT3 thus becomes a novel and impor-
tant molecular target for therapeutic
approaches to enhancing immune
recognition and/or breaking T cell toler-
ance, thereby increasing the host’s abili-
ty to impede cancer development and
progression.
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